Login
$CGON
$62.94 +$1.38 (2.24%) Close

Company Executives

$CGON Management Team

Mr. Robert Lapetina

Interim Principal Financial and Accounting Officer

Age 50
Compensation -
Sex Male

Mr. Joshua Patterson

Chief Compliance Officer

General Counsel and Secretary

Age 49
Compensation -
Sex Male

Mr. Arthur Kuan

Chairman of the Board

Chief Executive Officer

Age 34
Compensation $11.17M USD
Sex Male

Mr. Ambaw Bellete

President

Chief Operating Officer

Age 54
Compensation $5.241M USD
Sex Male

Dr. Vijay Kasturi

Chief Medical Officer

Age 57
Compensation -
Sex Male

Mr. Jim DeTore

Interim Principal Financial and Accounting Officer

Age 61
Compensation -
Sex Male
Directors
7
serving now
Independent
6 of 6
stated in the proxy; 1 not stated
Average tenure
5.1 years
from year joined
CEO also chairs the board
Yes
Arthur Kuan
Director Age On board Independent Committees Other public boards 2025 pay Source
Christina Rossi
50 2025
1 year
Independent None stated Xilio Therapeutics, Inc. $575,150
Victor Tong, Jr.
42 2023
3 years
Independent None stated Aardvark Therapeutics, Inc. $467,627
Susan Graf
53 2023
3 years
Independent None stated Aardvark Therapeutics, Inc. $482,627
Brian Liu
37 2022
4 years
Independent None stated None stated $475,127
Arthur Kuan
35 2017
9 years
Not stated None stated Chunghwa Chemical Synthesis & Biotech (TPEX: 1762) Paid as CEO
James J. Mulé
73 2018
8 years
Independent None stated None stated $457,627
Leonard Post
73 2018
8 years
Independent None stated uniQure N.V. (Nasdaq: QURE) $500,127

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

1 disclosed in the proxy filed Apr 24, 2026
holders of more than 5% of our capital stock and entities with which certain of our directors are affiliated
holders of more than 5% of our capital stock listed above as well as entities with which certain of our directors are affiliated
Amount not stated

Investors' Rights Agreement providing registration rights and certain covenants; all rights except registration rights terminated upon the IPO closing on December 16, 2024.

With holders of our redeemable convertible preferred stock and certain holders of our common stock Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support